Atlas Trials

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

Clinical trial NCT04796688 · UNKNOWN

Trial details

NCT number
NCT04796688
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Lymphoblastic LeukemiaChronic Lymphoblastic LeukemiaB-cell Lymphoma
Start date
2021-03-10
Primary completion
2023-03-10
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.